A common heart failure medication may help prevent heart damage related to chemotherapy
November 18, 2024
November 18, 2024
DALLAS, Texas, Nov. 18 [Category: Health Care] -- The American Heart Association issued the following news release:
Research Highlights:
A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared to placebo among high-risk cancer patients being treated with anthracycline chemotherapy agents.
The risk of cardiomyopathy among high-risk cancer patients treated with anthracyclines who took sacubi . . .
Research Highlights:
A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared to placebo among high-risk cancer patients being treated with anthracycline chemotherapy agents.
The risk of cardiomyopathy among high-risk cancer patients treated with anthracyclines who took sacubi . . .